Showing results (1701-1710 of 2,288) with videos related to

Sort By:
Pageof 229
HIV Medicine|March 15, 2012
Pooled week 96 results of the phase III DUET-1 and DUET-2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interestP-M Girard, T B Campbell, B Grinsztejn, et al.
HIV Medicine|July 24, 2026
Colorectal cancer screening uptake and lesion detection in people living with HIV: A systematic review and meta-analysisMotoki Kaneko, Atsushi Sakuraba
HIV Medicine|September 7, 2026
HIV-related knowledge and stigma among healthcare workers in Greece: A secondary analysis of a European surveyCharalampos D Moschopoulos, Nikos Pantazis, Konstantinos Protopapas, et al.
HIV Medicine|January 4, 2026
Quality of life and associated factors among people living with HIV in Türkiye: A single-centre experienceIlkay Akbulut, Zeynep Sedef Varol, Sarp Singil, et al.
HIV Medicine|September 22, 2022
Correlation between CD4/CD8 ratio and neurocognitive performance during early HIV infectionLeah T Le, Richard W Price, Magnus Gisslén, et al.
HIV Medicine|October 19, 2022
Estimation of the determinants for HIV late presentation using the traditional definition and molecular clock-inferred dates: Evidence that older age, heterosexual risk group and more recent diagnosis are prognostic factorsEvangelia Georgia Kostaki, Stefanos Limnaios, Georgios Adamis, et al.
HIV Medicine|December 5, 2014
A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE studyH G Sprenger, N Langebeek, P G H Mulder, et al.
HIV Medicine|October 11, 2015
Immune activation in the course of HIV-1 infection: Causes, phenotypes and persistence under therapyM Younas, C Psomas, J Reynes, et al.
HIV Medicine|August 14, 2015
Independent association of subclinical coronary artery disease and emphysema in HIV-infected patientsG Besutti, P Raggi, S Zona, et al.
HIV Medicine|November 23, 2012
Metformin: a cheap and well-tolerated drug that provides benefits for viral infectionsJ Joven, J A Menéndez, L Fernandez-Sender, et al.
Pageof 229